Literature DB >> 18661762

Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis.

Hua-Song Zeng1, Xiao-Yan Xiong, Yan-Dan Wei, Hong-Wei Wang, Xiao-Ping Luo.   

Abstract

BACKGROUND: Macrophage activation syndrome (MAS) is a severe, potentially life-threatening condition induced by chronic rheumatic diseases, especially systemic-onset juvenile idiopathic arthritis (SoJIA) in childhood. This study aimed to analyze the clinical and laboratory characteristics of systemic-onset juvenile idiopathic arthritis (SoJIA) with macrophage activation syndrome (MAS) in 13 patients.
METHODS: Clinical and laboratory data of 13 SoJIA patients with MAS treated in our hospital from January 2003 to October 2007 were analyzed.
RESULTS: In the 13 patients, 9 were boys and 4 girls aged from 5 months to 12 years. Clinical manifestations were of no typical characteristics including persistent fever, anemia, arthritis, hepatosplenomegaly, lymph-adenopathy, dysfunction of the liver, abnormal fat metabolism, and hemophagocytic cells in the bone marrow. Two patients experienced acute respiratory distress syndrome, two had mutiorgan failure, and three died. The perforin A91V (NCBI:SNP rs35947132) gene in 6 patients was normal. Glucocorticoid and immunoimpressive therapy were effective in all patients and plasmapheresis used in one severe patient was also effective.
CONCLUSIONS: MAS is a serious complication of JIA, especially systemic-onset juvenile idiopathic arthritis. It is essentially important to recognize and treat MAS earlier in order to lower the mortality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18661762      PMCID: PMC7102092          DOI: 10.1007/s12519-008-0018-6

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  21 in total

Review 1.  Macrophage activation syndrome--what's in a name!

Authors:  Athimalaipet V Ramanan; Rayfel Schneider
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

Review 2.  Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?

Authors:  Alexei A Grom
Journal:  Arthritis Rheum       Date:  2004-03

3.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

4.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

Review 5.  Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.

Authors:  R Mouy; J L Stephan; P Pillet; E Haddad; P Hubert; A M Prieur
Journal:  J Pediatr       Date:  1996-11       Impact factor: 4.406

6.  A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis.

Authors:  Ilia Voskoboinik; Marie-Claude Thia; Joseph A Trapani
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

7.  Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis.

Authors:  Athimalaipet V Ramanan; Norman D Rosenblum; Brian M Feldman; Ronald M Laxer; Rayfel Schneider
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

8.  Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection.

Authors:  M Hadchouel; A M Prieur; C Griscelli
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

9.  Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome.

Authors:  Nobuaki Maeno; Syuji Takei; Hiroyuki Imanaka; Kimie Yamamoto; Kazumi Kuriwaki; Yoshifumi Kawano; Hiroshi Oda
Journal:  Arthritis Rheum       Date:  2004-06

10.  Liver involvement in the histiocytic disorders of childhood.

Authors:  Ronald Jaffe
Journal:  Pediatr Dev Pathol       Date:  2004-03-17
View more
  6 in total

1.  Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.

Authors:  Li-Xia Zou; Yun Zhu; Li Sun; Hui-Hui Ma; Si-Rui Yang; Hua-Song Zeng; Ji-Hong Xiao; Hai-Guo Yu; Li Guo; Yi-Ping Xu; Mei-Ping Lu
Journal:  World J Pediatr       Date:  2019-10-14       Impact factor: 2.764

2.  Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.

Authors:  Selin Aytaç; Ezgi Deniz Batu; Şule Ünal; Yelda Bilginer; Mualla Çetin; Murat Tuncer; Fatma Gümrük; Seza Özen
Journal:  Rheumatol Int       Date:  2016-08-10       Impact factor: 2.631

Review 3.  Macrophage activation syndrome: early diagnosis is key.

Authors:  Butsabong Lerkvaleekul; Soamarat Vilaiyuk
Journal:  Open Access Rheumatol       Date:  2018-08-31

4.  Evaluation of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis: A Single Center Experience.

Authors:  Pia Elkjær Høeg; Mia Glerup; Birgitte Mahler; Christian Høst; Troels Herlin
Journal:  Int J Rheumatol       Date:  2022-07-27

Review 5.  Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  V Boom; J Anton; P Lahdenne; P Quartier; A Ravelli; N M Wulffraat; S J Vastert
Journal:  Pediatr Rheumatol Online J       Date:  2015-12-03       Impact factor: 3.054

Review 6.  Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.

Authors:  Puja Mehta; Randy Q Cron; James Hartwell; Jessica J Manson; Rachel S Tattersall
Journal:  Lancet Rheumatol       Date:  2020-05-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.